Clinically available aldosterone receptor antagonists are used to treat DN, and proteinuria continues to be significantly reduced during spironolactone treatment; however, it should be noted that aldosterone receptor antagonists, such as spironolactone, increase the risk of hyperkalemia (229). The gene discussed is NR3C2; the disease is liver dysplastic nodule.